LC–MS metabolomics analysis of serum metabolites during neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03537-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Qiliang Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Rectal Neoplasms, Metabolomics, Neoadjuvant Therapy, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: This study aimed to investigate the serum metabolite profiles during neoadjuvant chemoradiotherapy (NCRT) in locally advanced rectal cancer (LARC) using liquid chromatography-mass spectrometry (LC-MS) metabolomics analysis. METHODS: 60 serum samples were collected from 20 patients with LARC before, during, and after radiotherapy. LC-MS metabolomics analysis was performed to identify the metabolite variations. Functional annotation was applied to discover altered metabolic pathways. The key metabolites were screened and their ability to predict sensitivity to radiotherapy was calculated using random forests and ROC curves. RESULTS: The results showed that NCRT led to significant changes in the serum metabolite profiles. The serum metabolic profiles showed an apparent separation between different time points and different sensitivity groups. Moreover, the functional annotation showed that the differential metabolites were associated with a series of important metabolic pathways. Pre-radiotherapy (3Z,6Z)-3,6-Nonadiena and pro-radiotherapy 1-Hydroxyibuprofen showed good predictive performance in discriminating the sensitive and non-sensitive group to NCRT, with an AUC of 0.812 and 0.75, respectively. Importantly, the combination of different metabolites significantly increased the predictive ability. CONCLUSION: This study demonstrated the potential of LC-MS metabolomics for revealing the serum metabolite profiles during NCRT in LARC. The identified metabolites may serve as potential biomarkers and therapeutic targets for the management of this disease. Furthermore, the understanding of the affected metabolic pathways may help design more personalized therapeutic strategies for LARC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Institute of Radiotherapy & Oncology, Soochow University, Suzhou, China.
- State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
- Department of Oncology, Nantong Haimen District People's Hospital, Jiangsu, China.
- Department of Radiation Oncology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Zitieren
APA
Peng, Q., Jiang, L., Shen, Y., Xu, Y., Shen, X., Zou, L., Zhu, Y., & Shen, Y. (2024). LC–MS metabolomics analysis of serum metabolites during neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03537-x
Vancouver
Peng Q, Jiang L, Shen Y, Xu Y, Shen X, Zou L, et al. LC–MS metabolomics analysis of serum metabolites during neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03537-x
BibTeX
@article{Peng2024,
author = {Peng, Qiliang and Jiang, Lili and Shen, Yi and Xu, Yao and Shen, Xinan and Zou, Li and Zhu, Yaqun and Shen, Yuntian},
title = {LC–MS metabolomics analysis of serum metabolites during neoadjuvant chemoradiotherapy in locally advanced rectal cancer},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03537-x}
}
EUVIMED